HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Nimmo A, Taylor DM, Ravanan R

Does Screening for Coronary Artery Disease Predict Cardiac Outcomes Following Renal Transplantation?

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:57A 2020


Screening for asymptomatic coronary artery disease (CAD) prior to transplantation aims to reduce perioperative cardiac events. There is conflicting evidence as to whether this is achieved.


Individuals recruited to the Access to Transplant and Transplant Outcome Measures (ATTOM) study in England who received a renal transplant between 2011-2017 were studied. Patient demographics and details of screening investigations from ATTOM were linked to outcome data from the Hospital Episode Statistics dataset.

Major Adverse Cardiac Events (MACE) comprised unstable angina, myocardial infarction, coronary bypass graft, coronary angioplasty or cardiac death. The effect of screening on MACE was analysed in propensity score-matched groups, using Cox survival analyses, up to 5 years post- transplant.


2572 individuals received a renal transplant; 51% underwent CAD screening (Figure 1). Age, ethnicity, ischaemic heart disease and diabetes were independently associated with screening. The incidence of MACE at 90 days, 1 and 5 years was 0.9%, 2.1% and 9.4%.

After propensity score matching, 1854 individuals were examined. There was no association between screening and MACE at 90 days (HR 0.68, 95% CI 0.28- 1.64), 1 year (HR 1.24, 95% CI 0.60–2.54) or 5 years (HR 1.31, 95% CI 0.95–1.79) (Figure 2).


Screening for CAD did not influence the rate of ischaemic cardiac events up to 5 years post- transplant. Units should review protocols with lengthy cardiac workup processes.

Factors associated with MACE following propensity score matching

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.